News of Note—ImmusanT, PaxVax and more

In this week's news of note, Cambridge biotech ImmusanT reeled in $40 million in Series C financing.

Here is some other vaccine news of note for the week.

> Cambridge, Massachusetts-based biotech ImmusanT reeled in a $40 million Series C as it develops Nexvax2, a therapeutic celiac disease vaccine. Release

> Nonprofits Médecins Sans Frontières and Knowledge Ecology International protested the National Institutes of Health's proposed Zika vaccine license transfer to the biotech PaxVax. Release

> Pfizer named former vaccine executive Albert Bourla as its chief operating officer. FiercePharma article

> On Novavax's third-quarter conference call, CEO Stanley Erck said the company could file for approval with its maternal RSV shot and for its NanoFlu vaccine in 2019. Seeking Alpha transcript